Masahiro Okada

Prof. Dr. Masahiro Okada

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2022 in European Radiology
Verified
Journal Article
Closed access
PDF file
KTKenichiro Tago
Kenichiro Tago
JTJitsuro Tsukada
Jitsuro Tsukada
NSNaohiro Sudo
Naohiro Sudo
KSKazu Shibutani
Kazu Shibutani
Masahiro OkadaMasahiro Okada
Masahiro Okada
TTTadatoshi Takayama
Tadatoshi Takayama

19 May 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
FWFeiqian Wang
Feiqian Wang
KNKazushi Numata
Kazushi Numata
MNMasayuki Nakano
Masayuki Nakano
MTMikiko Tanabe
Mikiko Tanabe
MCMakoto Chuma
Makoto Chuma
Shin MaedaShin Maeda
Shin Maeda
We attempted to establish an ultrasound (US) imaging-diagnostic system for histopathological grades of differentiation of hepatocellular carcinoma (HCC). We conducted a retrospective study of histopathologically confirmed 200 HCCs, classified as early (45 lesions), well- (31 lesions), moderately (68 lesions) or poorly differentiated (diff.) (56 lesions) HCCs. We performed grayscale US to estimate the presence/absence of halo and mosaic signs, Sonazoid contrast-enhanced US (CEUS) to determine vascularity (hypo/iso/hyper) of lesion in arterial and portal phase (PP), and echogenicity of lesion in post-vascular phase (PVP). All findings were of significance for the diagnosis of some (but not all) histological grades (p < 0.001–0.05). Combined findings with a relatively high diagnostic efficacy for early, poorly and moderately diff. HCC were a combination of absence of halo sign and isoechogenicity in PVP of CEUS (accuracy: 93.0%, AUC: 0.908), hypovascularity in PP (accuracy: 78.0%, area under the curve (AUC): 0.750), and a combination of isovascularity in PP and hypoechogenicity in PVP (accuracy: 75.0%, AUC: 0.739), respectively. On the other hand, neither any individual finding nor any combination of findings yielded an AUC of over 0.657 for the diagnosis of well-diff. HCC. Our study provides encouraging data on Sonazoid CEUS in the histological differential diagnosis of HCC, especially in early HCC, and the effectiveness of this imaging method should be further proved by prospective, large sample, multicenter studies.


12 December 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MMMariko Mizuno
Mariko Mizuno
KTKenichiro Tago
Kenichiro Tago
Masahiro OkadaMasahiro Okada
Masahiro Okada
YNYujiro Nakazawa
Yujiro Nakazawa
TATakayuki Arakane
Takayuki Arakane
TTTadatoshi Takayama
Tadatoshi Takayama
Our purpose was to compare the efficacy of liver and splenic volumetry (LV and SV), extracellular volume (ECV) on dual-layer spectral-detector CT scoring systems for estimating liver fibrosis (LF) in 45 patients with pathologically staged LF. ECV measured on CT value (HU-ECV), iodine density (ID-ECV), atomic number (Zeff-ECV), and electron density (ED-ECV), LV or SV/body surface area (BSA), albumin bilirubin grade (ALBI), model for end-stage liver disease (MELD) score, aspartate aminotransferase platelet ratio index (APRI), and fibrosis index based on the four factors (FIB-4) were recorded. Transient elastography was measured in 22 patients, and compared to ECV. No correlation was found between transient elastography and all ECVs. Area under the curve (AUC) for estimating F4 on transient elastography was 0.885 (95% CI 0.745–1.000). ALBI was weakly associated with LF (p = 0.451), while MELD (p < 0.001), APRI (p = 0.010), and FIB-4 (p = 0.010) were significantly associated with LF. SV/BSA had a higher AUC than MELD, APRI, and FIB-4 for estimating F4 (AUC = 0.815, 95% CI 0.63–0.999), but MELD (AUC = 0.799, 95% CI 0.634–0.965), APRI (AUC = 0.722, 95% CI 0.561–0.883), and FIB-4 (AUC = 0.741, 95% CI 0.582–0.899) had higher AUCs than ALBI. SV/BSA significantly contributed to differentiation for estimating F4; odds ratio (OR) was 1.304–1.353 (Reader 1–2; R1–R2), whereas MELD significantly contributed to the differentiation between F0–2 and F3–4; OR was 1.528–1.509 (R1–R2). AUC for SV/BSA and MELD combined was 0.877 (95% CI 0.748–1.000). In conclusion, SV/BSA allows for a higher estimation of liver cirrhosis (F4). MELD is more suitable for assessing severe LF (≥ F3–4). The combination of SV/BSA and MELD had a higher AUC than SV/BSA alone for liver cirrhosis (F4).


9 March 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
AFAkihiro Funaoka
Akihiro Funaoka
KNKazushi Numata
Kazushi Numata
ATAtsuya Takeda
Atsuya Takeda
YSYusuke Saigusa
Yusuke Saigusa
YTYuichiro Tsurugai
Yuichiro Tsurugai
Shin MaedaShin Maeda
Shin Maeda
Radiotherapy is one of the available curative therapies for hepatocellular carcinoma (HCC). We investigate the use of contrast-enhanced ultrasound using Sonazoid (SCEUS) in evaluating the efficacy of radiotherapy for HCC. We enrolled 59 patients with 59 HCCs in this retrospective study. Tumor size and tumor vascularity were evaluated using SCEUS before and 1, 3, 7, 10, and 13 months after radiotherapy. The median follow-up period was 44.5 months (range: 16–82 months). Of the HCCs, 95% (56/59) had no local recurrence, while 5% (3/59) did. At 13 months after radiotherapy, in cases with no local recurrence, SCEUS showed a reduction in tumor vascularity in all cases, while tumor size reduction (>30% reduction, compared with pre-radiotherapy) was observed in 82.1% (46/56). In all three cases of local recurrence, vascularity and tumor size reduction were not observed during the follow-up period and residual HCCs were demonstrated pathologically. Compared with cases with local recurrence, tumor size reduction and reduction in tumor vascularity (p < 0.001) were significantly greater in cases with no local recurrence at 13 months after radiotherapy. SCEUS may be useful in evaluating radiotherapy efficacy for HCC.